doi: 10.1161/01.RES.0000253090.54488.81
© 2006 American Heart Association, Inc.
Editorials |
Phospholemman and the Cardiac Sodium Pump
Protein Kinase C, Take a Bow
From the Institute for Cardiovascular Research (W.F.), Ninewells Hospital, University of Dundee, UK; and the Cardiovascular Division (M.J.S.), King’s College London, UK.
Correspondence to Dr William Fuller, University of Dundee, Vascular Diseases Unit, Institute for Cardiovascular Research, Ninewells Hospital & Medical School, Dundee DD1 9SY, United Kingdom. E-mail w.fuller{at}dundee.ac.uk
See related article, pages 1376–1383
Key Words: phospholemman • FXYD • protein kinase C • Na/K pump
In excitable tissues, the activity of the plasmalemmal sodium/potassium ATPase (Na/K pump) is vital for the maintenance of normal electrical activity and ion gradients. In cardiac muscle, the transsarcolemmal sodium (Na) gradient established by the Na/K activity is essential not only for generating the rapid upstroke of the action potential but also for driving a number of ion exchange and transport processes that are crucial for normal cellular function, excitation contraction coupling, ion homeostasis and the control of cell volume. These Na-dependent membrane transporters include those responsible for the regulation of other ions (such as the sodium calcium exchanger (NCX), Na/H exchanger and Na-HCO3 cotransporter), as well as those involved in the movement of substrates and amino acids.1 By determining the set point for NCX, the Na/K pump controls the predominant mechanism of transmembrane calcium (Ca) flux, and hence indirectly controls intracellular Ca load and myocardial contractility. Interventions that influence either the activity of the Na/K pump, or indirectly the transmembrane sodium gradient, can therefore profoundly affect normal cardiac function.
Phospholemman, a type 1 transmembrane protein, is the predominant quantitative site of phosphorylation by protein kinase A (PKA) and protein kinase C (PKC) in cardiac sarcolemma.2 PKA phosphorylates serine 68 and PKC phosphorylates serines 63 and 68 in phospholemman. For a long time following its cloning in 1991,3 the physiological role of phospholemman was unclear. Indeed, writing in this journal in 1998, researchers noted that "As a major target for hormone-stimulated phosphorylation in the heart, the physiological function of phospholemman is likely to be an important one",4 however they were unable to suggest what this function may be. Various roles have now been proposed: 1) regulation of cell volume; 2) regulation of cardiac NCX; and 3) regulation of cardiac Na/K pump. Despite its size (only 72 amino acids), phospholemman is certainly a busy protein in cardiac myocytes.
The description in 2000 of a new gene family of ion transport regulators termed "FXYD" led to considerable progress in defining the physiological function of phospholemman.5 In cardiac myocytes, phospholemman (FXYD1) associates with the Na/K pump.6 Evidence from several laboratories supports the notion that phospholemman provides the link between cardiac kinases and the Na/K pump.7–9 Phosphorylation of phospholemman by PKA at serine 68 is associated with Na/K pump activation,7–10 and it has been proposed that phospholemman regulates the Na/K pump in a manner analogous to regulation of the calcium ATPase SERCA 2a by phospholamban: phosphorylation leading to disinhibition through elevated substrate affinity. In phospholemman deficient mice, ß-adrenergic stimulation of the Na/K pump is absent.9
Sympathetic stimulation of cardiac myocytes involves activation of PKA, via ß-adrenergic receptors, and PKC, via 
-adrenergic receptors. Whereas a considerable amount of effort has been dedicated to investigating the effect of PKA agonists on phospholemman and the cardiac Na/K pump, the effect of PKC phosphorylation of phospholemman has remained undefined. In this issue of Circulation Research, Han et al11 have investigated the effect of PKC activation on Na/K pump function, and the role played in this by phospholemman.
Every laboratory has their favorite method of measuring Na/K pump activity. The power of the research presented by Han et al11 lies in their use of 3 different techniques to investigate Na/K pump in freshly isolated mouse cardiomyocytes. Measurement of intracellular Na using the Na sensitive dye SBFI assesses the Na/K pump-dependent extrusion of Na after a period of pump inhibition. Simultaneous measurement of intracellular Na and Na/K pump current using 3 to 5 M
patch electrodes defines Na/K pump currents over a range of intracellular sodium. Low resistance patch electrodes measure Na/K pump currents at a single intracellular Na. So, not only is the transporting function of the Na/K pump assessed as the generation of an outward current (the exchange of 3Na for 2K), it is also assessed as the extrusion of its intracellular substrate (Na) as a function of that substrate concentration. All 3 techniques agree that PKC activation with phorbol ester increases Na/K pump Vmax, but is without effect on the enzyme’s Na affinity. Crucially, PKC-dependent stimulation of Na/K pump is absent in phospholemman deficient mice, indicating that, as for PKA, phospholemman provides the functional link between kinase and Na/K pump.
Sympathetic stimulation of the heart activates both PKA and PKC. Han et al11 have gone on to investigate the interaction of these 2 pathways in regulating the Na/K pump. Interestingly, there appears to be little overlap between the 2. PKA activation reduces K0.5 for Na and PKC activation increases Vmax regardless of the prior state of the myocyte. Likewise, PLM is further phosphorylated by PKA at serine 68 following PKC activation and vice versa. Hence in vivo, sympathetic stimulation of the mouse heart activates separate complementary pathways leading to Na/K pump activation at the level of both substrate affinity and Vmax. Physiologically, increased Na extrusion during sympathetic stimulation may limit the Na load induced by increased heart rate. While this may limit the associated positive inotropy, by favoring Ca extrusion by NCX it may also play a role in limiting Na and Ca overload, diastolic dysfunction and arrhythmias. Researchers have previously suggested that different isoforms of the catalytic subunit of the cardiac Na/K pump are subject to different regulatory mechanisms.8,12 An intriguing possibility raised by Han et al11 is that PKA and PKC target different Na/K pump isoforms through their phosphorylation of phospholemman. This highlights a key and hitherto unexplored issue: which proteins direct activated kinases to phospholemman, and what subpopulations of phospholemman are present in cardiac myocytes? The present article suggests that phospholemman exists in at least two subpopulations: one accessible only to PKA and one only to PKC. This implies that only a proportion of the Na/K pump is available to PKA, and a proportion to PKC. The authors speculate that these subpopulations of the Na/K pump represent the two isoforms of the catalytic subunit expressed in cardiac myocytes: 1 and 2.
The data presented by Han et al11 fit with a general scheme proposed by several laboratories, that phospholemman when unphosphorylated inhibits and when phosphorylated activates the Na/K pump. However the specifics of this scheme appear intricate. In reporting that serine 68 phosphorylated phospholemman increases K0.5 for Na whereas serine 63 and 68 phosphorylated phospholemman increases Vmax without effect on K0.5, the authors raise a complex biophysical question. Despite the presence of phosphate on serine 68 following PKC phosphorylation of phospholemman, no effect is observed on the K0.5 for Na. This implies that phosphorylation of serine 63 abrogates the effect of serine 68 phosphorylation, as well as increasing Na/K pump Vmax. This does not sit well with the concept of phosphorylation of phospholemman simply reducing its interaction with the Na/K pump. The relationship between phospholemman and Na/K pump is clearly more complex than that between phospholamban and SERCA2a in the sarcoplasmic reticulum.
To complicate matters further, in purified membrane fractions from phospholemman knockout and wild type hearts, other researchers have described reduced Na/K pump activity in the knockout compared with wild type13: the opposite to that seen in the present study, and to what you would predict if phospholemman is simply a Na/K pump inhibitor. What this probably emphasizes is that comparing wild type with knockout between different laboratories is difficult. The wild type is a mixed population of phosphorylated and unphosphorylated phospholemman, and the relative proportions of these are determined by the adrenergic state of the heart on preparation. In other words, the more your mice are scared, the more phospholemman is phosphorylated.
The observation that phospholemman forms ion channels in lipid membranes led to the proposal that it regulates cell volume,14 and recent work has supported the idea that phospholemman forms complexes with itself,15,16 although no laboratory has yet produced evidence that phospholemman regulates cardiomyocyte cell volume. Intriguingly, phospholemman is also reported to regulate cardiac NCX: phosphorylation of phospholemman by PKA is associated with NCX inhibition,17 and there is convincing evidence that phospholemman interacts physically with NCX.18 Whether phospholemman may really moonlight in so many different physiological roles remains to be seen. It is noteworthy and surely relevant that NCX and the Na/K pump are found together in a functional complex in cardiac myocytes.19,20 The position of phospholemman in this complex will doubtless be the subject of further investigation.
 |
Acknowledgments |
|---|
Sources of Funding
This work was supported by Intermediate Fellowship FS/03/052 from the British Heart Foundation, and an Academic Fellowship from Research Councils UK.
Disclosures
None.
|
Footnotes |
|---|
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
 Top References |
|---|
1. Bers DM, Barry WH, Despa S. Intracellular Na+ regulation in cardiac myocytes. Cardiovasc Res. 2003; 57: 897–912.
2. Presti CF, Jones LR, Lindemann JP. Isoproterenol-induced phosphorylation of a 15-kilodalton sarcolemmal protein in intact myocardium. J Biol Chem. 1985; 260: 3860–3867.
3. Palmer CJ, Scott BT, Jones LR. Purification and complete sequence determination of the major plasma membrane substrate for cAMP-dependent protein kinase and protein kinase C in myocardium. J Biol Chem. 1991; 266: 11126–11130.
4. Chen Z, Jones LR, O’Brian JJ, Moorman JR, Cala SE. Structural domains in phospholemman: a possible role for the carboxyl terminus in channel inactivation. Circ Res. 1998; 82: 367–374.
5. Sweadner KJ, Rael E. The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression. Genomics. 2000; 68: 41–56.[CrossRef][Medline] [Order article via Infotrieve]
6. Crambert G, Fuzesi M, Garty H, Karlish S, Geering K. Phospholemman (FXYD1) associates with Na,K-ATPase and regulates its transport properties. Proc Natl Acad Sci U S A. 2002; 99: 11476–11481.
7. Fuller W, Eaton P, Bell JR, Shattock MJ. Ischemia-induced phosphorylation of phospholemman directly activates rat cardiac Na/K-ATPase. FASEB J. 2004; 18: 197–199.
8. Silverman BZ, Fuller W, Eaton P, Deng J, Moorman JR, Cheung JY, James AF, Shattock MJ. Serine 68 phosphorylation of phospholemman: acute isoform-specific activation of cardiac Na/K ATPase. Cardiovasc Res. 2005; 65: 93–103.
9. Despa S, Bossuyt J, Han F, Ginsburg KS, Jia LG, Kutchai H, Tucker AL, Bers DM. Phospholemman-phosphorylation mediates the beta-adrenergic effects on Na/K pump function in cardiac myocytes. Circ Res. 2005; 97: 252–259.
10. Lifshitz Y, Lindzen M, Garty H, Karlish SJ. Functional interactions of phospholemman (PLM) (FXYD1) with Na+,K+-ATPase. Purification of alpha1/beta1/PLM complexes expressed in Pichia pastoris. J Biol Chem. 2006; 281: 15790–15799.
11. Han F, Bossuyt J, Despa S, Tucker AL, Bers DM Phospholemman-Phosphorylation Mediates the PKC-Dependent Effects on Na/K-Pump Function in Cardiac Myocytes. Circ Res. 2006. 99: 1376–1383.
12. Gao J, Wymore R, Wymore RT, Wang Y, McKinnon D, Dixon JE, Mathias RT, Cohen IS, Baldo GJ. Isoform-specific regulation of the sodium pump by alpha- and beta-adrenergic agonists in the guinea-pig ventricle. J Physiol. 1999; 516: 377–383.
13. Jia LG, Donnet C, Bogaev RC, Blatt RJ, McKinney CE, Day KH, Berr SS, Jones LR, Moorman JR, Sweadner KJ, Tucker AL. Hypertrophy, increased ejection fraction, and reduced Na-K-ATPase activity in phospholemman-deficient mice. Am J Physiol Heart Circ Physiol. 2005; 288: H1982–H1988.
14. Moorman JR, Ackerman SJ, Kowdley GC, Griffin MP, Mounsey JP, Chen Z, Cala SE, O’Brian JJ, Szabo G, Jones LR. Unitary anion currents through phospholemman channel molecules. Nature. 1995; 377: 737–740.[CrossRef][Medline] [Order article via Infotrieve]
15. Beevers AJ, Kukol A. Secondary structure, orientation, and oligomerization of phospholemman, a cardiac transmembrane protein. Protein Sci. 2006; 15: 1127–1132.[CrossRef][Medline] [Order article via Infotrieve]
16. Bossuyt J, Despa S, Martin JL, Bers DM. Phospholemman phosphorylation alters its fluorescence resonance energy transfer with the Na/K-ATPase pump. J Biol Chem. 2006; 281: 32765–32773.
17. Zhang XQ, Ahlers BA, Tucker AL, Song J, Wang J, Moorman JR, Mounsey JP, Carl LL, Rothblum LI, Cheung JY. Phospholemman inhibition of the cardiac Na+/Ca2+ exchanger. Role of phosphorylation. J Biol Chem. 2006; 281: 7784–7792.
18. Wang J, Zhang XQ, Ahlers BA, Carl LL, Song J, Rothblum LI, Stahl RC, Carey DJ, Cheung JY. Cytoplasmic tail of phospholemman interacts with the intracellular loop of the cardiac Na+/Ca2+ exchanger. J Biol Chem. 2006; 281: 32004–32014.
19. Mohler PJ, Davis JQ, Bennett V. Ankyrin-B coordinates the Na/K ATPase, Na/Ca exchanger, and InsP3 receptor in a cardiac T-tubule/SR microdomain. PLoS Biol. 2005; 3: e423.[CrossRef][Medline] [Order article via Infotrieve]
20. Dostanic I, Schultz Jel J, Lorenz JN, Lingrel JB. The alpha 1 isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca exchanger in heart. J Biol Chem. 2004; 279: 54053–54061.
Related Article:
Circ. Res. 2006 99: 1376-1383.
This article has been cited by other articles:
 |
|
 |
|
  S. Bibert, S. Roy, D. Schaer, J.-D. Horisberger, and K. Geering Phosphorylation of Phospholemman (FXYD1) by Protein Kinases A and C Modulates Distinct Na,K-ATPase Isozymes J. Biol. Chem., January 4, 2008; 283(1): 476 - 486. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||